Pharsight

Daptomycin is owned by Hospira Inc.

Daptomycin contains Daptomycin.

Daptomycin has a total of 2 drug patents out of which 0 drug patents have expired.

Daptomycin was authorised for market use on 21 June, 2021.

Daptomycin is available in powder;intravenous dosage forms.

Daptomycin can be used as treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18, treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12.

The generics of Daptomycin are possible to be released after 11 September, 2033.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535	HOSPIRA INC	Daptomycin formulations and uses thereof	Sep, 2033 (10 years from now)
US9655946	HOSPIRA INC	Daptomycin formulations and uses thereof	Sep, 2033 (10 years from now)

Do you want to check out DAPTOMYCIN patents from before 2022?

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 21 June, 2021

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administerin...

Dosage: POWDER;INTRAVENOUS